UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| | ||
| (Address of principal executive offices) | (Zip Code) |
(
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
(e)
On September 26, 2024, Armata Pharmaceuticals, Inc. (the “Company”) disclosed that it had reached an agreement with Richard Rychlik, the Company’s Vice President, Corporate Controller, pursuant to which Mr. Rychlik’s employment would conclude effective as of September 30, 2024.
In connection with Mr. Rychlik’s separation, on September 30, 2024, the Company entered into a Confidential Separation and Release Agreement with Mr. Rychlik (the “Separation Agreement”) pursuant to which, in consideration for Mr. Rychlik’s general release of claims in favor of the Company and its affiliates, Mr. Rychlik will be entitled to the continued payment of his base salary through December 31, 2024 and subsidized COBRA premiums for the same period. Mr. Rychlik’s receipt of the foregoing payments and benefits is subject to his compliance with the Separation Agreement.
The foregoing summary of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, a copy of which is attached as Exhibit 10.1 to this report and is incorporated by reference herein.
- 2 -
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
| 10.1 | Confidential Separation and Release Agreement by and between Armata Pharmaceuticals, Inc. and Richard Rychlik dated as of September 30, 2024. |
| 104 | Cover Page Interactive Data File (embedded within XBRL document) |
- 3 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: October 3, 2024 | Armata Pharmaceuticals, Inc. | |
| By: | /s/ David D. House | |
| Name: | David D. House | |
| Title: | Senior Vice President, Finance and Principal Financial Officer | |
- 4 -